Exelixis Inc Operating Lease Cost
Exelixis Inc (EXEL) reported Operating Lease Cost of $23.89 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-10
- Exelixis Inc operating lease, cost for the quarter ending 2020-01-03 was $1.08M, a 78.74% increase year-over-year.
- Exelixis Inc operating lease, cost for the quarter ending 2019-09-27 was $692.00K, a 57.13% decline year-over-year.
- Exelixis Inc operating lease, cost for the quarter ending 2019-06-28 was $660.00K, a 30.67% decline year-over-year.
- Exelixis Inc operating lease, cost for the quarter ending 2018-12-28 was $602.00K.
- Exelixis Inc operating lease, cost for fiscal 2026 was $23.89M, a 13.02% decline from fiscal 2025.
- Exelixis Inc operating lease, cost for fiscal 2025 was $27.46M, a 5.23% decline from fiscal 2023.
- Exelixis Inc operating lease, cost for fiscal 2023 was $28.98M, a 58.21% increase from fiscal 2022.
- Exelixis Inc operating lease, cost for fiscal 2022 was $18.32M, a 243.49% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-01-02 | $23.89M 10-K · filed 2026-02-10 | |||
| 2025-01-03 | $27.46M 10-K · filed 2026-02-10 | |||
| 2023-12-29 | $28.98M 10-K · filed 2026-02-10 | |||
| 2022-12-30 | $18.32M 10-K · filed 2025-02-11 | |||
| 2021-12-31 | $5.33M 10-K · filed 2024-02-06 | |||
| 2021-01-01 | $4.83M 10-K · filed 2023-02-07 | |||
| 2020-01-03 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $1.77M derived: sum of 2 quarters · filed 2022-02-18 | $2.43M derived: sum of 3 quarters · filed 2022-02-18 | $2.84M 10-K · filed 2022-02-18 |
| 2019-09-27 | $692.00K 10-Q · filed 2019-10-30 | $1.35M derived: sum of 2 quarters · filed 2019-10-30 | $1.77M 10-Q · filed 2019-10-30 | |
| 2019-06-28 | $660.00K 10-Q · filed 2019-07-31 | $1.10M 10-Q · filed 2019-07-31 | ||
| 2018-12-28 | $602.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.22M derived: sum of 2 quarters · filed 2020-02-25 | $3.17M derived: sum of 3 quarters · filed 2020-02-25 | $4.19M 10-K · filed 2021-02-11 |
| 2018-09-28 | $1.61M 10-Q · filed 2019-10-30 | $2.57M derived: sum of 2 quarters · filed 2019-10-30 | $3.59M 10-Q · filed 2019-10-30 | |
| 2018-06-29 | $952.00K 10-Q · filed 2019-07-31 | $1.97M 10-Q · filed 2019-07-31 | ||
| 2017-12-29 | -$348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $638.00K derived: sum of 2 quarters · filed 2019-02-22 | $3.94M 10-K · filed 2019-02-22 | |
| 2017-09-29 | $986.00K 10-Q · filed 2018-11-01 | $4.29M 10-Q · filed 2018-11-01 | ||
| 2016-12-30 | $8.62M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |